| Literature DB >> 22749832 |
Ayan Lahiri1, Pierre Pochard, Laëtitia Le Pottier, Gabriel J Tobón, Boutahar Bendaoud, Pierre Youinou, Jacques-Olivier Pers.
Abstract
The B-cell activating factor belonging to the tumor-necrosis factor family BAFF contributes to autoimmune disorders. As such, BAFF might become a therapeutic target. However, this molecule has pleiotropic effects that are as numerous as they are varied. The real effect of each form (spliced, glycosylated, membrane bound, soluble, homotrimerized, heterotrimerized, multimerized) has not been well characterized yet. Consequently, conflicting results, regarding the serum concentrations of BAFF or its functional effect, exist in literature. BAFF quantification based on ELISA commercial kits was indeed found to be inaccurate. The complexity of the various forms of BAFF will be reviewed by focusing on the different structural aspects of the molecule. These data have particular implications for autoimmunity, not only because of the role of these factors on B cell growth and survival, but also their influence on the onset and severity of several autoimmune diseases.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22749832 DOI： 10.1016/j.jaut.2012.05.009
Source DB: PubMed Journal: J Autoimmun ISSN： 0896-8411 Impact factor: 7.094